Novolimus-eluting coronary stent - Elixir Medical

Drug Profile

Novolimus-eluting coronary stent - Elixir Medical

Alternative Names: DESolve bioresorbable novolimus eluting coronary stent system; DESolve novolimus eluting coronary stent system; DESolve Novolimus Eluting Coronary Stent System; DESolve® NXT Novolimus Eluting Bioresorbable Coronary Scaffold System; DESyne BD novolimus eluting coronary stent system; DESyne BD Novolimus Eluting Coronary Stent System; DESyne Biodegradable novolimus eluting coronary stent system; DESyne novolimus eluting coronary stent system; DESyne Novolimus Eluting Coronary Stent System; DESyne® Nx Novolimus Eluting Coronary Stent System; Elixir DESyne Coronary Stent System; Excella Novolimus™-Eluting Coronary Stent System; Novolimus-eluting stent

Latest Information Update: 04 Nov 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Elixir Medical Corporation
  • Class Cardiovascular therapies; Macrolides
  • Mechanism of Action Immunosuppressants; MTOR protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Coronary artery restenosis

Most Recent Events

  • 01 Nov 2016 Positive initial 6-month efficacy data from the DESolve™ Cx clinical trial in Coronary artery restenosis (Prevention) released by Elixir Medical
  • 15 Oct 2015 Efficacy data from the DESolve® Nx trial in Coronary artery restenosis (prevention) released by Elixir Medical
  • 03 Mar 2015 Phase III development is ongoing for Coronary artery restenosis (Prevention) in Australia, Brazil and New Zealand
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top